Regeneron

+$16.20 (+2.66%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Regeneron and other ETFs, options, and stocks.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

CEO
Leonard S. Schleifer
Employees
9,123
Headquarters
Tarrytown, New York
Founded
1988

REGN Key Statistics

Market cap
67.22B
Price-Earnings ratio
9.98
Dividend yield
—
Average volume
887.34K
High today
$625.00
Low today
$601.89
Open price
$608.29
Volume
736.05K
52 Week high
$686.62
52 Week low
$441.00

REGN News

Benzinga18h

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have voluntarily withdrawn their application with the FDA for the expanded
Reuters21h

UPDATE 1-Regeneron, Sanofi withdraw FDA application for cancer drug's expanded use

(Adds details on Libtayo sales) Jan 28 (Reuters) - Regeneron Pharmaceuticals Inc and its partner Sanofi voluntarily withdrew their application with the U.S. dr
MarketWatch21h

Regeneron, Sanofi withdraw application for Libtaya as a cervical cancer treatment in the U.S.

Shares of Regeneron Pharmaceuticals Inc. REGN, +0.57% were down 0.1% in premarket trading on Friday after the company and Sanofi SNY, +3.00% said they will no l

REGN Earnings

$0.00
$8.60
$17.20
$25.80
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Estimated
$18.51 per share
Actual
Available Feb 4, Pre-Market

More REGN News

Reuters22h

Regeneron, Sanofi withdraw FDA application for Libtayo use in cervical cancer

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Br
AxiosJan 25

FDA limits use of Regeneron and Lilly COVID antibody treatments

The FDA said Monday it's limiting the use of two monoclonal antibody therapies as COVID-19 treatments because data indicates they're "highly unlikely" to be eff
The Wall Street JournalJan 24

Biden Administration Limits Use of Regeneron and Lilly Covid-19 Antibody Drugs

The Biden administration restricted the use of two monoclonal antibody drugs for Covid-19 because they are unlikely to be effective against the Omicron variant.
MarketWatchJan 24

FDA halts use of antibody drugs that don't work against omicron

WASHINGTON — COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don’t work against the omicron variant that now accounts
ReutersJan 24

U.S. FDA to restrict use of Regeneron, Lilly COVID antibody drugs - WaPo

Jan 24 (Reuters) - The U.S. Food and Drug Administration (FDA) is likely to restrict the use of COVID-19 antibody treatments from Regeneron and Eli Lilly as the
QuartzJan 22

Some US states still pushing ineffective covid antibody treatments

As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that fed
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure